

Ifu

USSN: 10/751,274
Dkt. No.: 6800-0063
SHE0063.00



PATENT

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 23, 2006.

2-23-06
Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kozlowski, et al.

Serial No.: 10/751,274

Filing Date: December 31, 2003

Title: HYDROLYTICALLY STABLE
MALEIMIDE-TERMINATED POLYMERS

Examiner: Robago, R.

Group Art Unit: 1713

Confirmation No.: 7476

Customer No.: 20855

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

Enclosed is an Information Disclosure Statement and accompanying Form
PTO/SB/08A for the above-identified patent application.

- ☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ In accordance with 37 C.F.R. §1.97(c), also enclosed is:
- ☐ the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
 - ☐ a statement as specified in 37 C.F.R. §1.97(e).
- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.

☐ Check No. ____ in the amount of \$____ for the total fee is attached.

☒ A return receipt postcard is also enclosed.


☐ Please charge \$_____ to Deposit Account No. 18-1648 for the total fee.
This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: February 23, 2006

By:



Susan T. Evans

Registration No. 38,443

ROBINS & PASTERNAK LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel.: (650) 493-3400
Fax: (650) 493-3440



PATENT

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 23, 2006.

2-23-06
Date

[Signature]
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kozlowski, et al.

Serial No.: 10/751,274

Filing Date: December 31, 2003

Title: HYDROLYTICALLY STABLE
MALEIMIDE-TERMINATED POLYMERS

Examiner: Robago R.

Group Art Unit: 1713

Confirmation No.: 7476

Customer No.: 20855

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.
§§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of the Foreign Patent Documents and Non Patent Literature Documents cited in the attached Form PTO/SB/08 are enclosed.
- ☒ No copy of the U.S. publications listed on the attached Form PTO/SB/08A are being provided because the Office waives the requirement under 37 C.F.R. 1.98 (a) (2) (i) for submitting a copy of each cited U.S. patent and each U. S. patent application publication for all U.S. national patent applications filed after June 30, 2003

- ☐ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. _____ to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Publication(s) _____ listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to PCT application serial no. _____ and mailed on _____.
- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication _____ (copy enclosed) claims priority from this non-English publication.
- ☒ Enclosed are abstracts of non-English publications, CN1110681, DE19652511, FR2206317, JP50110491, JP57192418, JP57205413, JP58015515, JP58040374, JP63277619, JP63286445, JP01062338, JP01088129, JP02149335, JP07132685, JP08041195, JP08117586, JP11349877, JP2000144033, JP2000143729, JP2000144041, JP2000306605, JP2000319252, JP2001172554, JP2001294777, JP2001322976, JP2002121221, JP2002265541, JP2002265442, JP2003040939, JP2003221443, and JP2003241337, for which full English translations have not been obtained.
- ☐ Enclosed is an English translation of non-English publication(s) _____ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. _____.


This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.


Respectfully submitted,

Date: February 23, 2006

By: 
Susan T. Evans
Registration No. 38,443

ROBINS & PASTERNAK LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel.: (650) 493-3400
Fax: (650) 493-3440

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/751,274	
			Filing Date	December 31, 2003	
			First Named Inventor	KOZLOWSKI, Antoni	
			Group Art Unit	1713	
			Examiner Name	Robago, R.	
			Attorney Docket Number	6800-0063	
Sheet	1	of	9		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	4,179,337	A	Davis, et al.	12-18-1979
	A2	4,179,551	A	Jones, et al.	12-18-1979
	A3	4,229,550	A	Jones, et al.	10-21-1980
	A4	4,251,626	A	Minamizono, et al.	02-17-1981
	A5	4,645,741	A	Inada	02-24-1987
	A6	4,675,414	A	Defusco, et al.	06-23-1987
	A7	4,839,345	A	Hiroshi, et al.	06-13-1989
	A8	5,166,322	A	Shaw, et al.	11-24-1992
	A9	5,527,528	A	Allen, et al.	06-18-1996
	A10	5,583,114	A	Barrows, et al.	12-10-1996
	A11	5,585,484	A	Acharya, et al.	12-17-1996
	A12	5,620,689	A	Allen, et al.	04-15-1997
	A13	5,641,856	A	Meurs, et al.	06-24-1997
	A14	5,766,897	A	Braxton	6-16-1998
	A15	5,844,020	A	Paine, et al.	12-01-1998
	A16	5,932,462	A	Harris, et al.	08-03-1999
	A17	6,001,958	A	Tapolsky, et al.	12-14-1999
	A18	6,139,819	A	Unger, et al.	10-31-2000
	A19	6,180,134	B1	Zalipsky, et al.	01-03-2001
	A20	6,180,598	B1	Nelson	01-30-2001
	A21	6,183,738	B1	Clarke	02-06-2001
	A22	6,210,707	B1	Papahadjopoulos, et al.	04-03-2001
	A23	6,261,537	B1	Klaveness, et al.	07-17-2001
	A24	6,271,339	B1	Thepot, et al.	08-07-2001
	A25	6,303,119	B1	Weisgerber, et al.	10-16-2001
	A26	6,306,923	B1	Thepot, et al.	10-23-2001
	A27	6,331,289	B1	Klaveness, et al.	12-18-2001
	A28	6,521,211	B1	Unger, et al.	02-18-2003
	A29	6,552,170	B1	Thompson, et al.	04-22-2003
	A30	6,602,498	B2	Shen, et al.	08-05-2003
	A31	2001/0044526	A1	Shen	11-22-2001
	A32	2002/0082345	A1	Kozlowski, et al.	06-27-2002
	A33	2003/0065134	A1	Sakanoue, et al.	04-03-2003
	A34	2003/0086867	A1	Lanza, et al.	05-08-2003
	A35	2003/0149307	A1	Hai, et al.	08-07-2003
	A36	2003/0162693	A1	Winslow, et al.	08-28-2003
	A37	2003/0170474	A1	Qiao, et al.	09-11-2003
	A38	2004/0167287	A1	Kozlowski, et al.	08-26-2004
	A39	2005/0014903	A1	Kozlowski, et al.	01-20-2005

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	2	of	9	Attorney Docket Number	6800-0063

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁵
		Office ³	Number ⁴	Kind Code			
	B1	CN	1110681	A	Shanghai Biochemistry Inst.	10-25-1995	
	B2	DE	19652544	A1	Wacker-Chemie G.m.b.H.	06-18-1998	
	B3	EP	3571110	A1	AKZO N.V.	03-07-1990	
	B4	EP	878482	A1	Dainippon Ink and Chemicals, Inc.	11-18-1998	
	B5	EP	0714402	B9	PolyMASC Pharmaceuticals	11-15-2000	
	B6	EP	1046394	A2	ImaRx Pharmaceutical Corp.	10-25-2000	
	B7	FR	2206317	A1	Institut Francais du Petrole	06-07-1974	
	B8	JP	50110491	A2	Furukawa Electric Co.	08-30-1975	
	B9	JP	57192418	A2	Mitsui Toatsu Chemicals, Inc.	11-26-1982	
	B10	JP	57205413	A2	Mitsui Toatsu Chemicals, Inc.	12-16-1982	
	B11	JP	58015515	A2	Mitsui Toatsu Chemicals, Inc.	01-28-1983	
	B12	JP	58040374	A2	Mitsui Toatsu Chemicals, Inc.	03-09-1983	
	B13	JP	63277619	A2	Nippon Oils & Fats Co., Ltd.	11-15-1988	
	B14	JP	63286445	A2	Bridgestone Corp.	11-24-1988	
	B15	JP	01062338	A2	Bridgestone Corp.	03-08-1989	
	B16	JP	01088129	A2	Nippon Oils & Fats Co., Ltd.	04-03-1989	
	B17	JP	02149335	A2	Nippon Oils & Fats Co., Ltd.	06-07-1990	
	B18	JP	07132685	A2	Fuji Photo Film Co., Ltd.	05-23-1995	
	B19	JP	08041195	A2	Nippon Oils & Fats Co., Ltd.	02-13-1996	
	B20	JP	08117586	A2	Nippon Oils & Fats Co., Ltd.	05-14-1996	
	B21	JP	11349877	A2	Tektronic, Inc.	12-21-1999	
	B22	JP	2000/144033	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B23	JP	2000/143729	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B24	JP	2000/144041	A2	Dainippon Ink and Chemicals, Inc.	05-26-2000	
	B25	JP	2000/306605	A2	Dainippon Ink and Chemicals, Inc.	11-02-2000	
	B26	JP	2000/319252	A2	Dainippon Ink and Chemicals, Inc.	11-21-2000	
	B27	JP	2001/172554	A2	Dainippon Ink and Chemicals, Inc.	06-26-2001	
	B28	JP	2001/294777	A2	Dainippon Ink and Chemicals, Inc.	10-23-2001	
	B29	JP	2001/322976	A2	Dainippon Ink and Chemicals, Inc.	11-20-2001	
	B30	JP	2002/121221	A2	Dainippon Ink and Chemicals, Inc.	04-23-2002	
	B31	JP	2002/265442	A2	Dainippon Ink and Chemicals, Inc.	09-18-2002	
	B32	JP	2002/265541	A2	Dainippon Ink and Chemicals, Inc.	09-18-2002	
	B33	JP	2003/040939	A2	Dainippon Ink and Chemicals, Inc.	02-13-2003	
	B34	JP	2003/221443	A2	Dainippon Ink and Chemicals, Inc.	08-05-2003	
	B35	JP	2003/241337	A2	Konishiroku Photo Ind.	08-27-2003	
	B36	WO	90/12874	A2	Genetics Inst.	11-01-1990	
	B37	WO	92/16221	A1	Synergen, Inc.	10-01-1992	
	B38	WO	94/21235	A1	Liposome Technology, Inc.	09-29-1994	
	B39	WO	94/21281	A1	Liposome Technology, Inc.	09-29-1994	
	B40	WO	95/11987	A1	Incyte Pharmaceuticals, Inc.	05-04-1995	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	3	of	9	Attorney Docket Number	6800-0063

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁸
		Office ⁶	Number ⁷	Kind Code			
	B41	WO	96/32841	A1	Burstein Laboratories, Inc.	10-24-1996	
	B42	WO	96/40285	A1	ImaRx Pharmaceutical Corp.	12-19-1996	
	B43	WO	98/02743	A1	Sensors Technology Co.	01-22-1998	
	B44	WO	98/11919	A2	Diagnocure, Inc.	03-26-1998	
	B45	WO	98/18500	A2	Nycomed Imaging AS	05-07-1998	
	B46	WO	98/22092	A1	Regents of the University of California	05-28-1998	
	B47	WO	98/30575	A1	Nexstar Pharmaceuticals, Inc.	07-16-1998	
	B48	WO	98/31383	A1	Pheonix Pharmacologics, Inc.	07-23-1998	
	B49	WO	99/03887	A1	Bolder Biotechnology, Inc.	01-28-1999	
	B50	WO	99/13919	A1	ImaRx Pharmaceutical Corp.	03-25-1999	
	B51	WO	99/48918	A1	The Proctor & Gamble Co.	09-30-1999	
	B52	WO	99/48928	A1	Sun Chemical Corp.	09-30-1999	
	B53	WO	99/55837	A2	Nycomed Imaging AS	11-04-1999	
	B54	WO	99/64460	A1	Celltech Therapeutics, Ltd.	12-16-1999	
	B55	WO	00/005582	A2	Burstein Laboratories, Inc.	02-03-2000	
	B56	WO	00/010974	A2	DSM N.V.	03-02-2000	
	B57	WO	00/016733	A2	The Proctor & Gamble Co.	03-30-2000	
	B58	WO	00/026256	A2	Centocor, Inc.	05-11-2000	
	B59	WO	00/045856	A2	ImaRx Pharmaceutical Corp.	08-10-2000	
	B60	WO	01/007484	A2	The Proctor & Gamble Co.	02-01-2001	
	B61	WO	01/007577	A2	The Proctor & Gamble Co.	02-01-2001	
	B62	WO	01/012154	A2	Celltech Chiroscience, Ltd.	02-22-2001	
	B63	WO	01/048052	A1	Kyowa Hakko Kogyo Co., Ltd.	07-05-2001	
	B64	WO	02/037850	A2	Dainippon Ink and Chemicals, Inc.	02-06-2002	
	B65	WO	02/025644	A1	Dainippon ink and Chemicals, Inc.	03-28-2002	
	B66	WO	02/035636	A1	Dainippon Ink and Chemicals, Inc.	05-02-2002	
	B67	WO	02/036161	A2	ImaRx Therapeutics, Inc.	05-10-2002	
	B68	WO	02/060978	A1	Kyowa Hakko Kogyo Co., Ltd.	08-08-2002	
	B69	WO	02/076428	A1	Alza Corp.	10-03-2002	
	B70	WO	02/083067	A2	Cryolife, Inc.	10-24-2002	
	B71	WO	02/100343	A2	Mandelmed, Inc.	12-19-2002	
	B72	WO	03/028640	A2	Univ. Vanderbilt	04-10-2003	
	B73	WO	03/034995	A2	Scripps Research Institute	05-01-2003	
	B74	WO	03/047549	A2	Mitsubishi Chem. Corp.	06-12-2003	
	B75	WO	03/057134	A2	Amgen, Inc.	07-17-2003	
	B76	WO	03/059363	A1	Sangart, Inc.	07-24-2003	
	B77	WO	03/061577	A2	Biogen, Inc.	07-31-2003	
	B78	WO	03/064462	A1	Chugai Pharmaceutical Co., Ltd.	08-07-2003	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

⁶ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁷ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁸ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<i>Complete if Known</i>		
			Application Number	10/751,274	
			Filing Date	December 31, 2003	
			First Named Inventor	KOZLOWSKI, Antoni	
			Group Art Unit	1713	
			Examiner Name	Robago, R.	
Sheet	4	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	C1	ACEVEDO, <i>et al.</i> , "Synthesis and Characterization of Imide End-Capped Oligomers of Poly(diethyleneglycol Terephthalate)," <i>J. of Applied Polymer Sci.</i> <u>38</u> (9):1745-1759 (1989)		
	C2	ACEVEDO, <i>et al.</i> , "Kinetic Study Of The Crosslinking Reaction Of Flexible Bismaleimides," <i>Polymer</i> <u>31</u> (10):1955-1959 (1990)		
	C3	ACEVEDO, <i>et al.</i> , "Semi-Interpenetrating Polymer Networks Of Maleimide End-Capped Oligoesters," <i>Polymer</i> <u>32</u> (12):2210-2214 (1991)		
	C4	ALAM, <i>et al.</i> , "The Importance Of Being Knotted: Effects Of The C-Terminal Knot Structure On Enzymatic And Mechanical Properties Of Bovine Carbonic Anhydrase II," <i>FEBS Letters</i> <u>519</u> (1-3):35-40 (2002)		
	C5	ALLEN, <i>et al.</i> , "Use Of The Post-Insertion Method For The Formation Of Ligand-Coupled Liposomes," <i>Cellular & Molecular Biol. Letters</i> <u>7</u> (3):889-894 (2002)		
	C6	ANDREADIS, <i>et al.</i> , "Use Of Immobilized PCR Primers To Generate Covalently Immobilized Dnas For In Vitro Transcription/Translation Reactions," <i>Nucleic Acids Research</i> <u>28</u> (2):II-VIII (2000)		
	C7	BESTMAN-SMITH, <i>et al.</i> , "Sterically Stabilized Liposomes Bearing Anti-HLA-DR Antibodies For Targeting The Primary Cellular Reservoirs Of HIV-1," <i>Biochimica et Biophysica Acta</i> <u>1468</u> (1-2):161-174 (2000)		
	C8	BIENIARZ, <i>et al.</i> , "Extended Length Heterobifunctional Coupling Agents For Protein Conjugations," <i>Bioconjugate Chem.</i> <u>7</u> :88-95 (1996)		
	C9	BLESSING, <i>et al.</i> , "Different Strategies For Formation Of PEGylated EGF-Conjugated PEI/DNA Complexes For Targeted Gene Delivery," <i>Bioconjugate Chem.</i> <u>12</u> (4):529-537 (2001)		
	C10	CHIAN, <i>et al.</i> , "Synthesis Of Bismaleimide Resin Containing The Poly(Ethylene Glycol) Side Chain: Curing Behavior And Thermal Properties," <i>J. of Applied Polymer Sci.</i> <u>85</u> (14):2935-2945 (2002)		
	C11	CHAIN, <i>et al.</i> , "Mechanical Properties And Morphology Of Poly(Ethylene Glycol)-Side-Chain-Modified Bismaleimide Polymer," <i>J. of Applied Polymer Sci.</i> <u>86</u> (3):715-724 (2002)		
	C12	CHLUBA, <i>et al.</i> , "Enhancement Of Gene Delivery By An Analogue Of α -MSH In A Receptor-Independent Fashion," <i>Biochimica et Biophysica Acta</i> <u>1510</u> (1-2):198-208 (2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	5	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	C13	CHRISTAKOPOULOS, <i>et al.</i> , "Enhancement Of pH-Stability Of A Low Molecular Mass Endoglucanase From Fusarium Oxysporum By Protein Pegylation," <i>Carbohydrate Res.</i> <u>314</u> (1-2):95-99 (1998)		
	C14	DAUTY, <i>et al.</i> , "Intracellular Delivery Of Nanometric DNA Particles Via The Folate Receptor," <i>Bioconjugate Chem.</i> <u>13</u> (4):831-839 (2002)		
	C15	DERYCKE, <i>et al.</i> , "Transferrin-Mediated Targeting Of Hypericin Embedded In Sterically Stabilized PEG-Liposomes," <i>International J. of Oncology</i> <u>20</u> (1):181-187 (2002)		
	C16	DIX, <i>et al.</i> , "Chain Extension And Crosslinking Of Telechelic Oligomers-I. Michael Additions Of Bismines To Bismaleimides And Bis(Acetylene Ketones)," <i>Eur. Polym. J.</i> <u>31</u> (7):647-652 (1995)		
	C17	FLEINER, <i>et al.</i> , "Studies On Protein-Liposome Coupling Using Novel Thiol-Reactive Coupling Lipids: Influence Of Spacer Length And Polarity," <i>Bioconjugate Chem.</i> <u>12</u> (4):470-475 (2001)		
	C18	FLES, <i>et al.</i> , "Synthesis And Spectroscopic Evidence Of N-Arylmaleimides And N-Aryl-2,3-Dimethylmaleimides," <i>Croatica Chemica Acta</i> , <u>76</u> (1):69-74 (2003)		
	C19	GAGNÉ, "Targeted Delivery Of Indinavir To HIV-1 Primary Reservoirs With Immunoliposomes," <i>Biochimica et Biophysica Acta</i> , <u>1558</u> (2):198-210, (2002)		
	C20	GAÍNA, <i>et al.</i> , "Bismaleimide Resins Containing Urethanic Moieties," <i>J of Macromolecular Sci. - Pure and Appl. Chem.</i> <u>A34</u> (12):2435-2449 (1997)		
	C21	GHENEIM, <i>et al.</i> , "Diels-Alder Reactions With Novel Polymeric Dienes And Dienophiles: Synthesis Of Reversibly Cross-Linked Elastomers," <i>Macromolecules</i> <u>35</u> (19):7246-7253 (2002)		
	C22	GUSENS, <i>et al.</i> , "Targeting Of The Photocytotoxic Compound AIPcS4 To Hela Cells By Transferring Conjugate PEG-Liposomes," <i>Intern. J. of Cancer</i> <u>101</u> (1):78-85 (2002)		
	C23	GOODSON, <i>et al.</i> , "Site-Directed Pegylation Of Recombinant Interleukin-2 At Its Glycosylation Site," <i>Biotech.</i> <u>8</u> :343-346 (1990)		
	C24	HAI, <i>et al.</i> , "Synthesis Of Water-Soluble, Nonimmunogenic Polyamide Cross-Linking Agents," <i>Bioconjugate Chem.</i> <u>9</u> (6):645-654 (1998)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	6	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹
	C25	HAI, <i>et al.</i> , "Polymerization Of Diaspirin Cross-Linked Hemoglobin (DCLHb) With Water-Soluble, Non-immunogenic Polyamide Cross-Liking Agents," <i>Bioconjugate Chem.</i> <u>10</u> (6):1013-1020 (1999)		
	C26	HEIMBUCH, <i>et al.</i> , "Composites Of Vinyl Polystyrylpyridine/Bismaleimide-Aliphatic Ether Copolymers," <i>SAMPE Quarterly</i> <u>20</u> (3):17-21 (1989)		
	C27	HILL, <i>et al.</i> , "Diels-Alder Bioconjugation Of Diene-Modified Oligonucleotides," <i>J. Org. Chem.</i> <u>66</u> (16):5352-5358 (2001)		
	C28	HUWYLER, <i>et al.</i> , "Bypassing Of P-glycoprotein Using Immunoliposomes," <i>J. of Drug Targeting</i> <u>10</u> (1):73-79 (2002)		
	C29	ISHIDA, <i>et al.</i> , "Targeted Delivery And Triggered Release Of Liposomal Doxorubicin Enhances Cytotoxicity Against Human B Lymphoma Cells," <i>Biochimica et Biophysica Acta</i> , <u>1515</u> (2):144-158, (2001)		
	C30	JUSZCZAK, <i>et al.</i> , "UV Resonance Raman Study Of β 93-Modified Hemoglobin A: Chemical Modifier-Specific Effects And Added Influences Of Attached Poly(Ethylene Glycol)," <i>Biochemistry</i> <u>41</u> (1):376-385 (2002)		
	C31	KIRPOTIN <i>et al.</i> , "Sterically Stabilized Anti-HER2 Immunoliposomes : Design And Targeting To Human Breast Cancer Cells In Vitro," <i>Biochemistry</i> <u>36</u> (1):66-75 (1997)		
	C32	KIRCHMEIER, <i>et al.</i> , "Correlations Between The Rate Of Intracellular Release Of Endocytosed Liposomal Doxorubicin And Cytotoxicity As Determined By A New Assay," <i>J. of Liposome Res.</i> <u>11</u> (1):15-29 (2001)		
	C33	KLEY, <i>et al.</i> , "Synthesis Of Novel Thiol-Reactive Amphiphilic Lipids Based On Cholesterol For Protein-Liposome Coupling," <i>Monatshefte für Chemie</i> <u>129</u> (3):319-327 (1998)		
	C34	KOGAN, "The Synthesis Of Substituted Methoxy-Poly(Ethyleneglycol) Derivatives Suitable For Selective Protein Modification," <i>Synthetic Communications</i> <u>22</u> (16):2417-2424 (1992)		
	C35	KUEHNE, <i>et al.</i> , "Synthesis And Characterization Of Membrane-Active GALA-OKT9 Conjugates," <i>Bioconjugate Chemistry</i> <u>12</u> (5):742-749 (2001)		
	C36	KULLBERG, <i>et al.</i> , "Development Of EGF-Conjugated Liposomes For Targeted Delivery Of Boronated DNA-Binding Agents," <i>Bioconjugate Chem.</i> <u>13</u> (4):737-743 (2002)		

Examiner Signature	Date Considered	
---------------------------	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/751,274
				Filing Date	December 31, 2003
				First Named Inventor	KOZLOWSKI, Antoni
				Group Art Unit	1713
				Examiner Name	Robago, R.
Sheet	7	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹
	C37	LEE, <i>et al.</i> , "A New Gene Delivery Formulation Of Polyethylenimine/DNA Complexes Coated With PEG Conjugated Fusogenic Peptide," <i>Journal of Controlled Release</i> <u>76</u> (1-2):183-192 (2001)		
	C38	LU, <i>et al.</i> , "Preparation And Biological Evaluation Of Polymerizable Antibody Fab' Fragment Targeted Polymeric Drug Delivery System," <i>Journal of Controlled Release</i> <u>74</u> (1-3):263-268 (2001)		
	C39	MAKMURA, <i>et al.</i> , "Development Of A Sensitive Assay To Detect Reversibly Oxidized Protein Cysteine Sulfhydryl Groups," <i>Antioxidants & Redox Signaling</i> <u>3</u> (6):1105-1118 (2001)		
	C40	MANJULA, <i>et al.</i> , "Cys-93-β-Succinimidophenyl Polyethylene Glycol 2000 Hemoglobin A. Intramolecular Cross-Bridging Of Hemoglobin Outside The Central Cavity," <i>The J. of Biological Chemistry</i> <u>275</u> (8):5527-5534 (2000)		
	C41	MANJULA, <i>et al.</i> , "Site-Specific PEGylation Of Hemoglobin At Cys-93(β): Correlation Between The Colligative Properties Of The PEGylated Protein And The Length Of The Conjugated PEG Chain," <i>Bioconjugate Chem.</i> <u>14</u> :464-472 (2003)		
	C42	MAO, <i>et al.</i> , "Chitosan-DNA Nanoparticles As Gene Carriers: Synthesis, Characterization And Transfection Efficiency," <i>J. of Controlled Release</i> <u>70</u> (3):399-421 (2001)		
	C43	MARUYAMA, <i>et al.</i> , "Targeting Efficiency Of PEG-Immunoliposome-Conjugated Antibodies At PEG Terminals," <i>Advaced Drug Delivery Reviews</i> <u>24</u> (2,3):235-242 (1997)		
	C44	MARUYAMA, <i>et al.</i> , "Targetability Of PEG-Immunoliposomes Conjugating Antibodies At The Ends Of PEG Chains," <i>Polymer Preprints</i> <u>38</u> (1):541-542 (1997)		
	C45	MENEZES, <i>et al.</i> , "Cellular Trafficking And Cytotoxicity Of Anti-CD19-Targeted Liposomal Doxorubicin In B Lymphoma Cells," <i>Journal of Liposome Research</i> <u>9</u> (2):199-228 (1999)		
	C46	MEYER, <i>et al.</i> , "Cationic Liposomes Coated With Polyethylene Glycol As Carriers For Oligonucleotides," <i>The J. of Biological Chemistry</i> , <u>273</u> (25):15621-15627 (1998)		
	C47	MOREIRA, <i>et al.</i> , "Targeting Stealth Liposomes In A Murine Model Of Human Small Cell Lung Cancer," <i>Biochimica et Biophysica Acta</i> <u>1515</u> (2):167-176 (2001)		
	C48	OLIVER, <i>et al.</i> , "Synthesis Of Pegylated Immunonanoparticles," <i>Pharmaceutical Res.</i> <u>19</u> (8):1137-1143 (2002)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/751,274	
			Filing Date	December 31, 2003	
			First Named Inventor	KOZLOWSKI, Antoni	
			Group Art Unit	1713	
			Examiner Name	Robago, R.	
Sheet	8	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹
	C49	PERRET, <i>et al.</i> , "Versatile Decoration Of Glass Surfaces To Probe Individual Protein-Protein Interactions And Cellular Adhesion," <i>Langmuir</i> <u>18</u> (3):846-854 (2002)		
	C50	Pierce Product Catalog "SMCC (Succinimidyl 4-[N-Maleimidomethyl]Cyclohexane-1-Carboxylate)," Product No. 22360 (2002)		
	C51	REDDY, <i>et al.</i> , "Folate-Targeted, Cationic Liposome-Mediated Gene Transfer Into Disseminated Peritoneal Tumors," <i>Gene Therapy</i> <u>9</u> (22):1542-1550 (2002)		
	C52	ROMANI, <i>et al.</i> , "Synthesis Of Unsymmetrical Cystine Peptides: Directed Disulfide Pairing With The Sulfenohydrazide Method," <i>Chem. of Peptides and Proteins</i> <u>2</u> :29-34 (1984)		
	C53	SAPRA, <i>et al.</i> , "Targeting Of Immunoliposomal Vincristine To Hematological Malignancies," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater. Controlled Release Soc.</i> <u>28</u> :582-583 (2001)		
	C54	SAPRA, <i>et al.</i> , "Internalizing Antibodies Are Necessary For Improved Therapeutic Efficacy Of Antibody-Targeted Liposomal Drugs," <i>Cancer Res.</i> <u>62</u> (24):7190-7194 (2002)		
	C55	SCHMIDT, <i>et al.</i> , "Force Tolerances Of Hybrid Nanodevices," <i>Nano Letters</i> <u>2</u> (11):1229-1233 (2002)		
	C56	Shearwater Catalog, "Polyethylene Glycol And Derivatives For Biomedical Applications," Shearwater Corporation, pp. 1-17 (2001)		
	C57	SHI, <i>et al.</i> , "Noninvasive Gene Targeting To The Brain," <i>Proceed. Of the Nat'l Academy of Sci. of the U.S.A.</i> <u>97</u> (13):7567-7572 (2000)		
	C58	SHI, <i>et al.</i> , "Brain-Specific Expression Of An Exogenous Gene After I.V. Administration," <i>Proceed. Of the Nat'l Academy of Sci. of the U.S.A.</i> <u>98</u> (22):12754-12759 (2001)		
	C59	SHUKLA, <i>et al.</i> , "Synthesis And Biological Evaluation Of Folate Receptor-Targeted Boronated PAMAM Dendrimers As Potential Agents For Neutron Capture Therapy," <i>Bioconjugate Chem.</i> <u>14</u> (1):158-167 (2003)		
	C60	SOUZA, <i>et al.</i> , "Membrane-Active Properties Of α -MSH Analogs: Aggregation And Fusion Of Liposomes Triggered By Surface-Conjugated Peptides," <i>Biochimica et Biophysica Acta</i> <u>1558</u> (2):222-237 (2002)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/751,274	
			Filing Date	December 31, 2003	
			First Named Inventor	KOZLOWSKI, Antoni	
			Group Art Unit	1713	
			Examiner Name	Robago, R.	
Sheet	9	of	9	Attorney Docket Number	6800-0063

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	C61	TAKIZAWA, <i>et al.</i> , "Targetability Of The Pendant Type Polyethyleneglycol-Immunoliposomes In Vivo," <i>Drug Delivery System</i> <u>13</u> (6):407-414 (1998)		
	C62	TANG, <i>et al.</i> , "Preparation Of A New Pegylation Reagent For Sulfhydryl-Containing Polypeptide," <i>Tetrahedron Letters</i> <u>35</u> (35):6515-6516 (1994)		
	C63	TESSMAR, <i>et al.</i> , "Amine-Reactive Biodegradable Diblock Copolymers", <i>Biomacromolecules</i> <u>3</u> (1):194-200 (2002)		
	C64	TSUTSUMI, <i>et al.</i> , "Site-Specific Chemical Modification With Polyethylene Glycol Of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity And Reduces Animal Toxicity And Immunogenicity," <i>Proceed. of the Nat'l Academy of Sci. of the U.S.A.</i> <u>97</u> (15):8548-8553 (2000)		
	C65	TURNER, <i>et al.</i> , "The Transfection Of Jurkat T-Leukemic Cells By Use Of pH-Sensitive Immunoliposomes," <i>Journal of Liposome Research</i> <u>12</u> (4):311-334 (2002)		
	C66	VARGAS, <i>et al.</i> , "Diels-Alder Modification Of Poly(Ethylene Terphthalate-Co-Anthracene-2,6-Carboxylate) With N-Substituted Maleimides," <i>J. of Polymer Sci.</i> <u>40</u> (19):3256-3263 (2002)		
	C67	VREELAND, <i>et al.</i> , "Molar Mass Profiling Of Synthetic Polymers By Free-Solution Capillary Electrophoresis Of DNA-Polymer Conjugates," <i>Anal. Chem.</i> <u>73</u> (8):1795-1803, (2001)		
	C68	WU, <i>et al.</i> , "p53 Protein Oxidation In Cultured Cells In Response To Pyrrolidine Dithiocarbamate: A Novel Method For Relation The Amount Of p53 Oxidation In Vivo To The Regulation Of p53-Responsive Genes", <i>Biochem. J.</i> , <u>351</u> (1):87-93, (2000)		
	C69	WÜNSCH, <i>et al.</i> , "A New Method For The Selective Synthesis of Unsymmetrical Cystine Peptides," <i>Peptides; Proceedings of the 17th European Peptide Symposium</i> , pp. 183-188 (1982)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.